Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Autor:	Tapia MD; Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore., Findlow H; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, United Kingdom., Idoko OT; Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia., Preziosi MP; Meningitis Vaccine Project, PATH, Ferney-Voltaire, France Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland., Kulkarni PS; Serum Institute of India, Ltd, Pune., Enwere GC; Meningitis Vaccine Project, PATH, Ferney-Voltaire, France., Elie C; Centers for Disease Control and Prevention, Atlanta, Georgia., Parulekar V; DiagnoSearch Life Sciences, Mumbai, India., Sow SO; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Haidara FC; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Diallo F; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Doumbia M; Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali., Akinsola AK; Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia., Adegbola RA; GlaxoSmithKline Vaccines, Wavre, Belgium., Kampmann B; Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia., Chaumont J; Meningitis Vaccine Project, PATH, Ferney-Voltaire, France., Martellet L; Meningitis Vaccine Project, PATH, Ferney-Voltaire, France., Marchetti E; Meningitis Vaccine Project, PATH, Ferney-Voltaire, France., Viviani S; Meningitis Vaccine Project, PATH, Ferney-Voltaire, France., Tang Y; Meningitis Vaccine Project, PATH, Seattle, WA., Plikaytis BD; Centers for Disease Control and Prevention, Atlanta, Georgia., LaForce FM; Serum Institute of India, Ltd, Pune., Carlone G; Centers for Disease Control and Prevention, Atlanta, Georgia., Borrow R; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, United Kingdom.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2015 Nov 15; Vol. 61 Suppl 5, pp. S514-20.
DOI:	10.1093/cid/civ672
Abstrakt:	Background: Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated. Methods: African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA). Results: Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination. Conclusions: A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination. Clinical Trials Registration: ISRTCN78147026. (© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu